SAN DIEGO, Feb 24, 2005 /PRNewswire-FirstCall via COMTEX/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders, today announced that it will report its financialresults for the fourth quarter and year ended December 31, 2004 on Thursday,March 3, 2005, after the U.S. financial markets close.
Uli Hacksell, Ph.D., Chief Executive Officer, and Thomas H. Aasen, VicePresident and Chief Financial Officer, will host a conference call and webcaston Thursday, March 3, 2005 at 4:30 p.m. Eastern Time to discuss ACADIA'sfinancial results and provide an update on the company's business.
The conference call may be accessed by dialing 800-295-3991 forparticipants from the United States or Canada and 617-614-3924 forinternational callers (reference participant passcode 39550576). Theconference call will also be webcast live on ACADIA's website atwww.acadia-pharm.com, under the investor relations section, and will bearchived there until March 17, 2005.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of novel treatmentsfor central nervous system disorders. ACADIA currently has four drug programsin clinical development as well as a portfolio of preclinical and discoveryassets directed at large unmet medical needs, including schizophrenia,Parkinson's disease, neuropathic pain, and glaucoma. Using its proprietarydrug discovery platform, ACADIA has discovered all of the drug candidates inits product pipeline. ACADIA's corporate headquarters and biology researchfacilities are located in San Diego, California and its chemistry researchfacilities are located near Copenhagen, Denmark.
Contacts:
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
+1 858-558-2871
ir@acadia-pharm.com